|
Sernova Corp. (TSX-V:SVA) is a Canadian based health sciences company focused on commercialization of innovative medical technologies. Its lead project is Sertolin, a technology for reversing insulin dependent diabetes through transplanted pig islet and Sertoli cells. The islet cells produce insulin that is compatible with human bodies while the Sertoli cells protect the islet cells from attack by the person's immune system. Sernova has the exclusive right to the patents and associated intellectual property for the therapeutic use of Sertoli cells in the United States, Canada and most major industrialized nations.
Dr. David White - Principal Researcher |
Follow the link to listen to an interview with Dr. White in which he discusses the primary causes and effects of diabetes as well as the work being done through xenotransoplantation in an attempt to restore those affected back to health: Audio Interview
|
| |
Oct 15, 2008: News Releases: Jeffrey Bacha Appointed to Sernova Board of Directors - Grant of Stock Opti... (more...)
Oct 10, 2008: Related Media & Articles: CTV National News: Avis Favaro Reports on Controversial Research Picked up ... (more...)
Aug 13, 2008: News Releases: Sernova Corp.'s Diabetes Technology Featured at International Congress of t... (more...)
| |
